Clinical trial NCT06626711: Effect of Propofol and Sevoflurane Anesthesia on HSP70 Expression in Tumor Cells
Official title: Effect of Propofol and Sevoflurane Anesthesia on HSP70 Expression in Tumor Cells A Prospective, Single-center, Pilot, Randomized Study
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: EARLY_PHASE1
Conditions: Anesthesia
Cancer Recurrence
Cancer
Keywords: Cancer
Anesthesia
Sevoflurane
Propofol
Lead sponsor: Saint Petersburg State University, Russia
Sponsor class: OTHER
Collaborators: name: Institute of Cytology of the Russian Academy of Sciences
name: The Russian Science Foundation
First posted: 2024-10-04
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The goal of this clinical trial is to learn if sevoflurane-based inhalational anesthesia (s-IA) and propofol-based total intravenous anesthesia (p-TVA) have different effects on HSP70 expression in different types of tumour cells. The main questions it aims to answer are:

* if p-TVA/s-IA increase or suppress HSP70 expression in tumor cells in comparison with a pre-anesthesia level;
* does this change in HSP70 expression cause any difference in vital characteristics of tumor cells, such as proliferation, apoptosis, colony formation and migration.

Researchers will compare p-TVA with s-IA by ability of these types of anesthesia to change the HSP70 expression level and modulate HSP70-mediated effects in tumor cells.

Participants will:

* be randomly allocated to p-TVA or s-IA groups;
* donate 12 ml of blood before anesthesia induction and 12 ml after 2 hours of anesthesia.

The blood serum will be used to prepare cell medium. After exposure to this medium, cells from different tumor types will be investigated using cytological and molecular biological methods.

Detailed description: This study will be conducted in adult cancer patients who undergo planned radical or palliative tumor resection and signed informed consent. Patients with diabetes mellitus, HIV, hepatitis B and C, as well as patients who undergo emergency surgery will not be included to the study. Patients will be randomly allocated to propofol-based TVA (p-TVA) and sevoflurane-based IA (s-IA) groups. After the collection of blood before the anesthesia induction and in 2 hours of anesthesia, probes will be centrifuged to prepare serum. Cell medium will contain 50% of blood serum. Different tumor cell lines (human lung adenocarcinoma A549, large cell lung carcinoma NCI-H460, human colorectal adenocarcinoma DLD1) will be exposed to the cell medium for 4 hours what corresponds to an approximate duration of anesthesia for oncology surgery. HSP70 expression level will be determined using SDS-PAGE (polyacrilamide gel electrophoresis) and Western-blot analysis (intracellular HSP70 content), ELISA of cell medium (extracellular HSP70 expression) and confocal microscopy.

The A549 cell line with stable knockdown of HSP70 developed by shRNA will be used to distinguish HSP70-based effects of cell medium from p-TVA and s-IA groups on vital characteristics of tumor cells, including proliferation (MTT assay), apoptosis (LDH cytotoxicity assay), colony formation and migration (the Wound healing assay).

Researchers will compare HSP70 expression levels and vital characteristics of tumor cells exposed to patient serum before and after each type of anesthesia, as well as p-TVA group with s-IA group.

Eligibility criteria: Inclusion Criteria:

* Diagnosed malignant neoplasm
* Planned surgery for radical or palliative tumor resection
* Age over 18 years
* Signed informed consent

Exclusion Criteria:

* Diabetes mellitus type 2
* HIV, hepatitis B or C
* Emergency surgery
* Known or suspected allergy to studied drugs
* Other conditions when one of the types of anesthesia is more preferable (hemodynamic disorders, bronchial asthma etc)

Primary outcomes:
measure: HSP70 expression in tumor cells in vitro
timeFrame: 24 hours after exposition with patients serum.
Secondary outcomes:
measure: LDG cytotoxicity
timeFrame: 24 hours after exposition with patients serum.
measure: MTT test
timeFrame: 24 hours after exposition with patients serum.
measure: Wound healing test
timeFrame: 72 hours after exposition with patients serum.
measure: Cell colonies formation
timeFrame: 7 days after exposition with patients serum.
Other outcomes:
Locations:
city: Saint Petersburg
country: Russian Federation
facility: Saint Petersburg State University Hospital
Study officials:
References: